본문 바로가기
KERD
논문KCI 등재

조현병 환자의 금연 약물 치료

Pharmacotherapy for Smoking Cessation in Patients with Schizophrenia

김유나|정도운|김성진
대한조현병학회 (Korean Academy of Schizophrenia)|2018.04|대한조현병학회지 (Korean Journal of Schizophrenia Research)|제21권 제1호|pp. 21-27

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

조현병SchizophreniaSmoking약물치료니코틴NicotineDrug therapy흡연.
주제분류정신과학

초록

Schizophrenia is a major chronic mental illness with various symptoms that is often accompanied by substance use disorders. Patients with schizophrenia have a higher smoking rate than the general population and a lower smoking cessation success rate. Further, their motivation for smoking cessation is often low. Individuals with schizophrenia that are past or present cigarette smokers are more difficult to treat in terms of psychotic symptoms, are more likely to have physical illnesses, and have higher mortality rates. A variety of treatments, both pharmacological and non-pharmacological, are used to aid smoking cessation in patients with schizophrenia. Among these, bupropion, varenicline, and nicotine replacement therapy can be safely used in patients with schizophrenia, and several studies have demonstrated their effects. Cigarette smoking is an important health problem. The study of smoking cessation in individuals with schizophrenia may help improve their ability to function and their quality of life through active evaluation and treatment.

Abstract

Schizophrenia is a major chronic mental illness with various symptoms that is often accompanied by substance use disorders. Patients with schizophrenia have a higher smoking rate than the general population and a lower smoking cessation success rate. Further, their motivation for smoking cessation is often low. Individuals with schizophrenia that are past or present cigarette smokers are more difficult to treat in terms of psychotic symptoms, are more likely to have physical illnesses, and have higher mortality rates. A variety of treatments, both pharmacological and non-pharmacological, are used to aid smoking cessation in patients with schizophrenia. Among these, bupropion, varenicline, and nicotine replacement therapy can be safely used in patients with schizophrenia, and several studies have demonstrated their effects. Cigarette smoking is an important health problem. The study of smoking cessation in individuals with schizophrenia may help improve their ability to function and their quality of life through active evaluation and treatment.

참고문헌 (58)

  1. Green AI, "Schizophrenia and co-occurring substance use disorder", Am J Psychiatry, 164, pp.402~408 (2007)
  2. Blanchard JJ, "Substance use disorders in schizophrenia: review, integration, and a proposed model", Clin Psychol Rev, 20, pp.207~234 (2000)
  3. Dickey B, "Schizophrenia, substance use disorders and medical co-morbidity", J Ment Health Policy Econ, 3, pp.27~33 (2000)
  4. Kelly C, "Cigarette smoking and schizophrenia", Adv Psychiatr Treat, 6, pp.327~331 (2000)
  5. Kandel D, "Prevalence and demographic correlates of symptoms of last year dependence on alcohol, nicotine, marijuana and cocaine in the U.S. population", Drug Alcohol Depend, 44, pp.11~29 (1997)
  6. Gandini S, "Tobacco smoking and cancer: a meta-analysis", Int J Cancer, 122, pp.155~164 (2008)
  7. Ambrose JA, "The pathophysiology of cigarette smoking and cardiovascular disease: an update", J Am Coll Cardiol, 43, pp.1731~1737 (2004)
  8. Ng M, "Smoking prevalence and cigarette consumption in 187 countries, 1980-2012", JAMA, 311, pp.183~192 (2014)
  9. Holford TR, "Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012", JAMA, 311, pp.164~171 (2014)
  10. Lasser K, "Smoking and mental illness: A population-based prevalence study", JAMA, 284, pp.2606~2610 (2000)
  11. de Leon J, "A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors", Schizophr Res, 76, pp.135~157 (2005)
  12. Thorndike AN, "US physicians’ treatment of smoking in outpatients with psychiatric diagnoses", Nicotine Tob Res, 3, pp.85~91 (2001)
  13. Goff DC, "Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects", Am J Psychiatry, 149, pp.1189~1194 (1992)
  14. Goff DC, "Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists", J Clin Psychiatry, 66, pp.183~194 (2005)
  15. Kelly DL, "Cigarette smoking and mortality risk in people with schizophrenia", Schizophr Bull, 37, pp.832~838 (2011)
  16. Hukkanen J, "Effect of nicotine on cytochrome P450 1A2 activity", Br J Clin Pharmacol, 72, pp.836~838 (2011)
  17. Barnes M, "Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use?", Aust N Z J Psychiatry, 40, pp.575~580 (2006)
  18. Adler LE, "Schizophrenia, sensory gating, and nicotinic receptors", Schizophr Bull, 24, pp.189~202 (1998)
  19. Lyon ER, "A review of the effects of nicotine on schizophrenia and antipsychotic medications", Psychiatr Serv, 50, pp.1346~1350 (1999)
  20. Sacco KA, "Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms", Arch Gen Psychiatry, 62, pp.649~659 (2005)
  21. Barr RS, "The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls", Neuropsychopharmacology, 33, pp.480~490 (2008)
  22. Hughes JR, "Prevalence of smoking among psychiatric outpatients", Am J Psychiatry, 143, pp.993~997 (1986)
  23. Smith RC, "Effects of cigarette smoking on psychopathology scores in patients with schizophrenia: an experimental study", Subst Abus, 22, pp.175~186 (2001)
  24. Lerman C, "Mediating mechanisms for the impact of bupropion in smoking cessation treatment", Drug Alcohol Depend, 67, pp.219~223 (2002)
  25. Hurt RD, "A comparison of sustained-release bupropion and placebo for smoking cessation", N Engl J Med, 337, pp.1195~1202 (1997)
  26. George TP, "A placebo controlled trial of bupropion for smoking cessation in schizophrenia", Biol Psychiatry, 52, pp.53~61 (2002)
  27. Evins AE, "A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia", J Clin Psychopharmacol, 25, pp.218~225 (2005)
  28. George TP, "A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia", Biol Psychiatry, 63, pp.1092~1096 (2008)
  29. Evins AE, "A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia", J Clin Psychopharmacol, 27, pp.380~386 (2007)
  30. Bloch B, "Preliminary effects of bupropion and the promoter region (HTTLPR) serotonin transporter (SLC6A4) polymorphism on smoking behavior in schizophrenia", Psychiatry Res, 175, pp.38~42 (2010)
  31. Tsoi DT, "Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis", Br J Psychiatry, 196, pp.346~353 (2010)
  32. Weiner E, "Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis", J Clin Psychiatry, 73, pp.95~102 (2012)
  33. Castelnovo A, "Occipital seizures and visual pseudohallucinations associated with the addition of bupropion to clozapine: a case report", J Clin Psychopharmacol, 35, pp.97~99 (2015)
  34. Mihalak KB, "Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors", Mol Pharmacol, 70, pp.801~805 (2006)
  35. Rollema H, "Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid", Neuropharmacology, 52, pp.985~994 (2007)
  36. Jeon DW, "Adjunctive varenicline treatment for smoking reduction in patients with schizophrenia: A randomized double-blind placebo-controlled trial", Schizophr Res, 176, pp.206~211 (2016)
  37. Williams JM, "A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder", J Clin Psychiatry, 73, pp.654~660 (2012)
  38. Evins AE, "Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial", JAMA, 311, pp.145~154 (2014)
  39. Fatemi SH, "Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study", Schizophr Res, 146, pp.376~378 (2013)
  40. Tsoi DT, "Interventions for smoking cessation and reduction in individuals with schizophrenia", Cochrane Database Syst Rev (2013)
  41. Roberts E, "Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis", Addiction, 111, pp.599~612 (2016)
  42. Ahmed AI, "Neuropsychiatric adverse events of varenicline: a systematic review of published reports", J Clin Psychopharmacol, 33, pp.55~62 (2013)
  43. Anthenelli RM, "Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebocontrolled clinical trial", Lancet, 387, pp.2507~2520 (2016)
  44. Stead LF, "Nicotine replacement therapy for smoking cessation", Cochrane Database Syst Rev (2008)
  45. Chou KR, "The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia", Int J Nurs Stud, 41, pp.321~330 (2004)
  46. Baker A, "A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder", Am J Psychiatry, 163, pp.1934~1942 (2006)
  47. Caponnetto P, "Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study", Int J Environ Res Public Health, 10, pp.446~461 (2013)
  48. King AC, "Naltrexone alteration of acute smoking response in nicotine-dependent subjects", Pharmacol Biochem Behav, 66, pp.563~572 (2000)
  49. Szombathyne-Meszaros Z, "Oral naltrexone treatment for alcohol dependence in schizophrenia is not effective for smoking cessation", Alcohol Clin Exp Res, 34, pp.176A~ (2010)
  50. de Leon J, "Does clozapine decrease smoking?", Prog Neuro-Psychopharmacol Biol Psychiatry, 29, pp.757~762 (2005)
  51. Kelly DL, "Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia", Schizophr Res, 103, pp.161~168 (2008)
  52. Sacco KA, "Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia", Schizophr Res, 107, pp.332~333 (2009)
  53. Awad AG, "The burden of schizophrenia on caregivers: a review", Pharmacoeconomics, 26, pp.149~162 (2008)
  54. Rice DP, "The economic impact of schizophrenia", J Clin Psychiatry, 60(Suppl 1), pp.4~6 (1999)
  55. Allender S, "The burden of smoking-related ill health in the UK", Tob Control, 18, pp.262~267 (2009)
  56. Dixon L, "Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes", Schizophr Res, 35(Suppl), pp.S93~S100 (1999)
  57. Ziedonis D, "Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report", Nicotine Tob Res, 10, pp.1691~1715 (2008)
  58. Tidey JW, "Effects of smoking abstinence on cigarette craving, nicotine withdrawal, and nicotine reinforcement in smokers with and without schizophrenia", Nicotine Tob Res, 16, pp.326~334 (2014)

관련 논문AI추천

한국인 조현병 환자에서 흡연과 사회인구학적, 임상적 특성과의 관계김용식, 김종우, 김철응, 나경세, 류성곤, 민경준, 박기창, 안용민, 윤진상, 이종일, 조다함, 한진희대한신경정신의학회 · 신경정신의학2012 · 제51권 제5호정신분열증 입원환자에서 니코틴과 항정신병 약물의 상관관계 규명을 위한 니코틴 패취 적용 연구김종우, 반건호, 유희정, 윤도준, 이기철대한생물치료정신의학회 · 생물치료정신의학2000 · 제6권 제1호일 대학병원에서 양극성장애 환자의 흡연 특성 : 정신분열병 환자와의 비교 연구김지혜, 김현진, 이강수, 조현상, 천덕희대한신경정신의학회 · 신경정신의학2006 · 제45권 제4호니코틴 중독의 평가와 치료한진희대한생물치료정신의학회 · 생물치료정신의학2002 · 제8권 제2호Tobacco Use in Bipolar DisorderDaniel Thomson, Lesley Berk, Marta Rapado-Castro, MIchael Berk, Olivia M. Dean, Pernille K. Ellegaard, Seetal Dodd, Shae E. Quirk대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2015 · 제13권 제1호Effect of Varenicline on Tardive Dyskinesia: A Pilot StudyAlisa R. Gutman, E. Cabrina Campbell, John Northrop, Rosalind M. Berkowitz, Shirley H. Leong, Stanley N. Caroff대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2021 · 제19권 제2호

이 간행물의 다른 논문 (3건)

정신의료기관 내 격리·강박 수행과 간호 전략김석헌, 김성완, 성지은, 김수진pp. 1-8항정신병약물에 의한 안구운동발작과 발작성 지각변화 증후군정인원, 정희연, 윤탁, 정성훈, 김용식, 김임열pp. 9-20조현병 외래환자에서 낙인을 많이 느끼는 군과 적게 느끼는 군에서의임상 요인 비교김철권, 한정현pp. 28-36
원문 보기